RESEARCH ARTICLE

OXIDATIVE STRESS STATUS IN PATIENTS WITH TYPE2 DIABETES MELLITUS.

Selma. M Osman. M. Yousif¹, Mohammed S. M. Abdalla¹, E. M. A. Elmahdi² and Manal. Mohammed. Ramadan³.

1. Sudan Atomic Energy Commission, Khartoum.
2. University of Khartoum, Faculty of Medicine.
3. National Research Center in Cairo, Egypt.

Material and methods: Plasma levels of SOD, CAT and MDA were estimated in 50 Control and 140 diabetic patients divided into: DWC group consisted of diabetic patients without complications, CAD group consisted of patients with coronary artery disease, DN group consisted of patients with diabetic nephropathy, DNe group consisted of patients with diabetic neuropathy. Spectrophotometry and enzyme-linked immunosorbent assay (ELISA) techniques have been applied for determination of MDA, CAT and SOD respectively.

Results: comparing the levels of SOD and CAT in all groups, it was observed that the lowest concentration was in CAD, DN, DNe groups followed by DWC and control groups. Oxidative stress was found increased in CAD, DN, DNe groups as compared to DWC and control groups since, the highest concentration of MDA levels were observed in these groups.

A significant inverse correlation was observed of HbA1c, insulin and MDA with SOD, CAT in all diabetic groups. And a significant direct correlation between HbA1C and MDA was also observed in all diabetic groups.

Conclusion: The present study confirms susceptibility of diabetic patients to oxidative stress and that poor glycaemic control is associated with free radical-mediated lipid peroxidation. The present study arrived to the conclusion that hyperglycemia and oxidative stress present a high risk for development of diabetic complications and need early intervention.

Manuscript Info

Abstract

Background: Oxidative stress due to chronic hyperglycemia has been implicated in the pathogenesis of type 2 diabetes and its complications.

Objectives: To estimate the levels of antioxidant enzymes superoxide dismutase (SOD), catalase (CAT) and lipid peroxidation marker i.e. malondialdehyde (MDA) in type 2 DM patients with and without complications i.e., neuropathy, nephropathy and cardiovascular diseases compared to normal subjects. To access the association between oxidative stress and diabetes mellitus and development of its complication.

Materials and methods: Plasma levels of SOD, CAT and MDA were estimated in 50 Control and 140 diabetic patients divided into: DWC group consisted of diabetic patients without complications, CAD group consisted of patients with coronary artery disease, DN group consisted of patients with diabetic nephropathy, DNe group consisted of patients with diabetic neuropathy. Spectrophotometry and enzyme-linked immunosorbent assay (ELISA) techniques have been applied for determination of MDA, CAT and SOD respectively.

Results: comparing the levels of SOD and CAT in all groups, it was observed that the lowest concentration was in CAD, DN, DNe groups followed by DWC and control groups. Oxidative stress was found increased in CAD, DN, DNe groups as compared to DWC and control groups since, the highest concentration of MDA levels were observed in these groups.

A significant inverse correlation was observed of HbA1c, insulin and MDA with SOD, CAT in all diabetic groups. And a significant direct correlation between HbA1C and MDA was also observed in all diabetic groups.

Conclusion: The present study confirms susceptibility of diabetic patients to oxidative stress and that poor glycaemic control is associated with free radical-mediated lipid peroxidation. The present study arrived to the conclusion that hyperglycemia and oxidative stress present a high risk for development of diabetic complications and need early intervention.

Copy Right, IJAR, 2018., All rights reserved.

Corresponding Author:- Selma. M Osman. M. Yousif.
Address: - Sudan Atomic Energy Commission , Email: selmayousif@hotmail.com
Introduction:
Diabetes mellitus is a chronic disease with serious metabolic disturbances in carbohydrate, protein and fat metabolism characterized by hyperglycemia resulting from defects in insulin secretion, resistance to insulin action or both. The primary causative factor of oxidative stress in diabetes mellitus is hyperglycemia. Hyperglycemia is known to cause elevation in plasma free radical concentrations [1, 2]. Increased production of free radicals and diminishing antioxidant defense mechanisms can lead to damage of cellular organelles and enzymes, increased lipid peroxidation, and development of insulin resistance. These consequences of oxidative stress can promote the development of complications of diabetes mellitus such as coronary artery diseases, nephropathy, neuropathy, and foot ulceration [3].

Enzymes like Superoxide Dismutase (SOD) and Catalase (CAT) comprise natural cellular defense mechanism against these free radicals. Superoxide dismutase (SOD) is the antioxidant enzyme, plays important protective roles against cellular and histological damages that are produced by ROS. It facilitates the conversion of superoxide radicals into hydrogen peroxide and in the presence of other enzymes hydrogen peroxide is converted into oxygen and water [4]. CAT is the antioxidant enzyme, plays an important role against oxidative stress-generated complications such as diabetes and cardiovascular diseases [5]. CAT acts as main regulator of a highly reactive small molecule, hydrogen peroxide metabolism. It enzymatically converts hydrogen peroxide into oxygen and water and thus neutralizes it [6]. CAT protects pancreatic-cells from damage by hydrogen peroxide [7]. Increased risk of diabetes has been documented in patients with catalase deficiency.

Malondialdehyde (MDA) has been documented as a primary biomarker of free radical mediated lipid damage and oxidative stress [8]. Increased lipid peroxidation in diabetes induced many secondary chronic complications through peroxidative injury, like atherosclerosis and neural disorders [9, 10]. Therefore the aim of this study was to evaluate plasma lipid peroxidation marker, malondialdehyde (an oxidant) and antioxidant enzyme (superoxide dismutase and catalase) in type 2 diabetes mellitus patients with and without complications i.e., neuropathy, nephropathy and cardiovascular diseases compared to normal subjects. And also, to access the association between oxidative stress and diabetes mellitus and development of its complication.

Materials and methods:-
Study Design and Population:-
A total of 140 type II diabetic patients were recruited from Jabir Abu Eliz (the public diabetes Center) and People Teaching Hospital of the heart and chest in Khartoum State. Medical records were screened by specialist physicians. The patients of type 2 diabetes mellitus were divided into four groups: DWC group consisted of diabetic patients without complications; CAD group consisted of patients with coronary artery disease, diagnosed by clinical symptoms of angina pectoris, electrocardiogram examination Or documented myocardial infarction; DN group consisted of patients with diabetic nephropathy, evaluated by significant renal impairment such as abnormal creatinine or macroalbuminuria; DNe group consisted of patients with diabetic neuropathy(nervous system damage), diagnosed by the clinical examination of the patients. The diabetic patients received oral hypoglycemic agents like sulphonylureas or metformin. No patient was taking insulin in all the groups of diabetic patients.

Healthy control group, C group was selected. Healthy Control subjects and diabetic patients were matched with respect to age, sex, body mass index (BMI) as determined by the weight and height of patients. All individuals were non smokers. None had taken antioxidant vitamin supplements.

This study was conducted after taking ethical clearance from The Ministry of Health Khartoum state-planning management and training. Written informed consent was taken from the subjects prior to the study.

Samples Collection & Preparation:-
Fasting venous blood samples (5ml) were collected. Whole blood was used to for analysis of glycosylated hemoglobin (Hb A1C). For plasma preparation, Blood samples were collected in heparinized tubes, centrifuged 20-min at the speed of 2000-3000 r.p.m, for immediate analysis of glucose. Aliquots of plasma were frozen at ~20°C for further determinations of insulin, SOD, CAT and MDA.
Biochemical Analysis:-
Determinations of fasting blood glucose, HbA1c and insulin:-
Glucose was measured spectrophotometrically by oxidase/peroxidase method using reagents and standards obtained from BioSystems S.A [11]. HbA1c was measured quantitatively by Ichroma™ HbA1c fluorescence immunoassay (FIA), using reagents and standards obtained from Boditech Med Incorporated [12]. Insulin was measured quantitatively by insulin [521] IRMA assay system using reagents and standards obtained from IZOTOP.

Parameters of oxidative stress:-
Malonaldehyde (MDA) was estimated spectrophotometrically by thiobarbituric acid assay, using reagents and standards obtained from Biodiagnostic Co., Cairo, Egypt. Thiobarbituric acid (TBA) reacts with Malonaldehyde(MDA) to form thiobarbituric acid reactive product [13].

Superoxide dismutase (SOD) was measured by SOD ELIZA assay, using reagents and standards obtained from SunLong Biotech Co., LTD. Catalase (CAT) was estimated by calorimetrically enzymatic assay kit, using reagents and standards obtained from Biodiagnostic Co., Cairo, Egypt [14].

Statistical analysis:-
All analyses were performed using SPSS software (version20) for Windows. Statistical significance between the groups was analyzed by Independent Samples T –Test. and correlation between variables was studied by using Pearson’s correlation coefficient test. Multivariate model was performed with diabetes mellitus as a control variable; to find out the effect of variables independently for the development of diabetic complications. All parameters will be given as mean± standard error (SE). The criterion for significance will be p < 0.001.

Results:-
General Characteristics of the Study Participants:-
The general characteristics and biochemical parameters of all the study participants were summarized in Table 1. All Observations were recorded as (Mean± SE or %).

Plasma glucose, HbA1C, insulin and duration of the disease:-
Significant difference was observed between diabetic groups (DWC DN, DNe, CAD) and the control group for plasma glucose mean level which was high in all diabetic patients regardless of complications (107.8±2.7, 171.4±13, 183.0±13, 191.5±12.2) versus (88.8±0.9) for the control group, (P<0.001, P <0.001, P <0.001, P <0.001) respectively. The difference was also found to be statistically significant in DN, DNe, CAD groups when compared with DWC group, (P <0.001, P <0.001, P <0.001) respectively as shown on Table1.

Similar to glucose, Significant difference was found between diabetic groups (DWC, DN, DNe, CAD) and control group for plasma HbA1C mean level which was high in all diabetic patients regardless of complications (8.9±0.3, 10.0±0.4,10.3±0.3) versus (4.9±0.05), (P<0.001, P <0.001, P <0.001, P <0.001) respectively. The difference was also found to be statistically significant in DN, DNe, CAD groups when compared with DWC group (P <0.001, P <0.001, P <0.001) respectively as shown on Table1.

Significant difference was found between diabetic groups (DWC, DN, DNe, CAD) and control group for plasma insulin mean level which was high in all diabetic patients regardless of complications (5.8±0.8, 8.9±0.3, 10.0±0.4,10.3±0.3) versus (4.9±0.05), (P<0.001, P <0.001, P <0.001, P <0.001) respectively. The difference was also found to be statistically significant in DN, DNe, CAD groups when compared with DWC group (P <0.001, P <0.001, P <0.001) respectively, as shown on Table1.

Plasma Malonaldehyde (MDA) level:-
MDA level was significantly increased in all groups of type II diabetes mellitus (DWC, DN, CAD, DNe) when compared with control (9.2±0.2, 10.5±0.4, 11.4±0.4, 12.4±0.4) versus (6.7±0.1), (P<0.001, P <0.001, P <0.001, P <0.001) respectively. The difference was also found to be statistically significant in DN, CAD, DNe groups when compared with DWC group (P =0.014, P <0.001, P <0.001) respectively as shown on Table1.

Plasma Superoxide (SOD) and Catalase (CAT) levels:-
SOD level was significantly lower in all groups of type II diabetes mellitus (DWC, CAD, DNe, DN) when compared with control (254.9±4.9, 174.7±1.3, 150.0±1.4, 126.8±1.4) versus (363.9±4.9), (P<0.001, P <0.001, P <0.001, P <0.001, P
<0.001) respectively. The difference was also found to be statistically significant in CAD, DNe, DN groups when compared with DWC group (P<0.001, P<0.001, P<0.001) respectively as shown on Table1.

CAT level was significantly lower in all groups of type II diabetes mellitus (DWC, CAD, DN, DNe) when compared with control (299.4±3.2, 245.9±5.2, 194.7±5.1, 151.8±2.7) versus (413.9±3.4), (P<0.001, P<0.001, P<0.001, P<0.001) respectively. The difference was also found to be statistically significant in CAD, DN, DNe groups when compared with DWC group (P<0.001, P<0.001, P<0.001) respectively, as shown on Table1.

### Correlation of HbA1c with SOD, CAT, MDA and duration of diabetes:
- The study showed significant inverse correlation of HbA1c with SOD, CAT and significant direct correlation with MDA and duration of diabetes in all diabetic groups as shown on Table2.

### Correlation of MDA with SOD, CAT and duration of diabetes:
- The study showed significant inverse correlation of MDA with SOD and CAT and significant direct correlation with duration in all diabetic groups as shown on Table3.

### Correlation of insulin with SOD, CAT:
- The study showed significant inverse correlation of insulin with SOD and CAT in all diabetic groups as shown on Table3.

### Association of oxidative stress parameters with diabetic complications:
- To find out the effect of oxidative stress parameters independently for the development of diabetic complications (coronary artery disease, nephropathy, neuropathy) we performed the multivariate model with diabetes mellitus as a control variable. Multivariate analysis revealed that SOD, CAT, MDA, HbA1c, insulin and duration of diabetes were associated with CAD, DN and DNe as shown on Table4.

### Table1: Demographic and biochemical parameters of diabetic and control Subjects

|                         | Control Subjects | Diabetic Patients Type11 |
|-------------------------|------------------|-------------------------|
|                         | C Group          | DWC Group               |
| Number                  | 50               | 35                      |
| M/F ratio               | 17/18            | 17/18                   |
| Age (years)             | 54.5 ± 0.9       | 54.3 ± 1.1              |
| BMI (kg/m2)             | 25.0 ± 0.5       | 26.9 ± 0.9              |
| FBS (mg/dl)             | 88.8 ±0.9        | 107.8±2.7*              |
| HbA1C (%)               | 4.9±0.05         | 5.5±0.08*               |
| Insulin(mIU/L)          | 9.0±0.35         | 15.2±1.5*               |
| MDA (nmol/ml)           | 6.7±0.1          | 9.2±0.2*                |
| SOD (U/L)               | 363.9±4.9        | 254.9±4.9*              |
| CAT (U/L)               | 413.9±3.4        | 299.4±3.2               |

C, control; DWC, diabetic without complications; CAD, coronary artery disease; DN, diabetic nephropathy; DNe, diabetic neuropathy; BMI, Body mass index; FSB, fasting blood sugar; HbA1C, glycatedhemoglobin; MDA, Malondialdehyde; SOD, Superoxide dismutase; CAT, Catalase. Values are given as mean± standard error. *p<0.001 when C group compared with DWC, CAD, DN and DNe groups. p<0.001 =a when DWC group compared with CAD, DN and DNe groups.
Table 2: Correlation of HbA1c with SOD, CAT, MDA and duration in diabetic patients

|                               | DWC Group | CAD Group | DN Group | DNe Group |
|-------------------------------|-----------|-----------|----------|-----------|
|                               | R         | P         | R        | P         | R         | P         | R         | P         |
| HbA1c/ SOD                    | -.57      | <0.001    | -.78     | <0.001    | -.78      | <0.001    | -.80      | <0.001    |
| HbA1c/ CAT                    | -.64      | <0.001    | -.84     | <0.001    | -.78      | <0.001    | -.82      | <0.001    |
| HbA1c/ MDA                    | .33       | 0.002     | .73      | <0.001    | .67       | <0.001    | .61       | <0.001    |
| HbA1c/ duration               | .13       | .253      | .56      | <0.001    | .62       | <0.001    | .52       | <0.001    |

Correlation is significant at the 0.01 level (2-tailed). **; Correlation is significant at the 0.05 level (2-tailed). *; correlation is nonsignificant, ns

Table 3: Correlation of MDA and Insulin with SOD, CAT and Duration in Diabetic Patients

|                               | DWC Group | CAD Group | DN Group | DNe Group |
|-------------------------------|-----------|-----------|----------|-----------|
|                               | R         | P         | R        | P         | R         | P         | R         | P         |
| MDA/SOD                       | -.62      | <0.001    | -.76     | <0.001    | -.70      | <0.001    | -.80      | <0.001    |
| MDA/CAT                       | -.70      | <0.001    | -.76     | <0.001    | -.69      | <0.001    | -.80      | <0.001    |
| MDA/ Duration                 | -.10      | .518      | .39      | <0.001    | .43       | <0.001    | .39       | <0.001    |
| Insulin/ SOD                  | -.43      | <0.001    | -.46     | <0.001    | -.47      | <0.001    | -.53      | <0.001    |
| Insulin/ CAT                  | -.46      | <0.001    | -.44     | <0.001    | -.48      | <0.001    | -.55      | <0.001    |

Correlation is significant at the 0.01 level (2-tailed). **; Correlation is significant at the 0.05 level (2-tailed). *; correlation is nonsignificant, ns

Table 4: Multivariate model determining biochemical variables associated with diabetic complications

| Parameter             | B        | Std. error | t   | F  | Adjusted $R^2$ | P    | 95% CI       |
|-----------------------|----------|------------|-----|----|----------------|------|--------------|
| **CAD**               |          |            |     |    |                |      |              |
| SOD                   | .491     | .1         | 2.7 | 7.4| .085           | 0.008| .131 - .850  |
| CAT                   | .743     | .2         | 3.4 | 11.8| .135           | 0.001| .312 - 1.17  |
| MDA                   | .737     | .1         | 4.4 | 19.8| .214           | <0.001| .407 - 1.06  |
| HbA1c                 | 1.36     | .5         | 2.1 | 4.8 | .052           | .032 | .125 - 2.61  |
| Insulin               | .683     | .1         | 4.3 | 18.7| .205           | <0.001| .368 - 9.97  |
| Duration Of Diabetes  | .529     | .2         | 2.4 | 6.2 | .070           | .015 | .106 - 9.53  |
| **DN**                |          |            |     |    |                |      |              |
| SOD                   | .563     | .2         | 2.0 | 4.2 | .045           | 0.040 | .017 - 1.10  |
| CAT                   | .724     | .3         | 2.0 | 4.1 | .043           | 0.042 | .011 - 1.43  |
| MDA                   | .390     | .1         | 2.1 | 4.8 | .053           | .031 | .036 - 7.44  |
| HbA1c                 | 1.0      | .4         | 2.0 | 4.2 | .045           | .043 | .035 - 2.12  |
| Insulin               | .342     | .1         | 2.4 | 5.8 | .066           | .018 | .061 - 6.23  |
| Duration Of Diabetes  | .533     | .2         | 2.6 | 7.1 | .081           | .010 | .134 - 9.32  |
| **DNe**               |          |            |     |    |                |      |              |
| SOD                   | .541     | .2         | 2.3 | 5.6 | .063           | 0.020 | .087 - 9.94  |
| CAT                   | 1.02     | .4         | 2.2 | 4.8 | .053           | 0.031 | .099 - 1.95  |
| MDA                   | .502     | .2         | 2.2 | 5.1 | .056           | .027 | .060 - 9.44  |
| HbA1c                 | 1.7      | .5         | 2.7 | 7.3 | .084           | .008 | .461 - 3.02  |
| Insulin               | .518     | .1         | 4.1 | 17.4| .193           | <0.001| .271 - 7.65  |
| Duration Of Diabetes  | .794     | .1         | 19.6| 4.4 | .213           | <0.001| .437 - 1.15  |

CAD, coronary artery disease; DN, diabetic nephropathy; DNe, diabetic neuropathy; HbA1C, glycated hemoglobin; MDA, Malondialdehyde; SOD, Superoxide dismutase; CAT, Catalase; CI, confidence interval. *P < 0.05

**Discussion:**
Type II diabetes mellitus is characterized by chronic hyperglycemia which induces an increase of oxidative stress leading to an overproduction of reactive oxygen species (ROS) and free radical species associated with an impairment of antioxidant defence systems [15].
The aldehydic product of lipid peroxidation (MDA) is a biomarker of intensified lipid peroxidation and also indirect evidence of high free radical production in diabetes [16]. In the present study, the MDA level was found to be significantly increased in type II diabetic patients with different complications compared to patients without complications and to healthy subjects. The findings of this study are also in a good agreement with the findings of a previous study which showed that MDA levels in patients with diabetic neuropathy are \( \sim 40\% \) higher than diabetics without neuropathy and almost three times higher than healthy controls [17].

In this study, Superoxide dismutase (SOD) and catalase (CAT) levels were found to be significantly reduced in type II diabetic patients with different complications compared to patients without complications and to healthy subjects. The present findings were in a good agreement with the observations of Kimura et al [18] who have reported decreased SOD level in type II diabetic patients. Uzel et al [19] and Kedziora-Kornatowska et al [20] have also reported low SOD and catalase activities in type II diabetics compared to controls. In contrast, Aydin and his coworkers [21] have noticed that SOD activity is elevated while catalase activities are normal in erythrocytes of type II diabetics.

In this study, the insulin hormone level was found to be significantly increased in type II diabetic patients compared to healthy subjects. This result agrees with the theory of insulin resistance associated with hyperinsulinemia that promotes higher production of free radicals by NADPH-dependent mechanisms [22].

This study specifically focused on the correlation of HbA1c and insulin with antioxidant enzymes, superoxide dismutase and catalase. The study findings showed a significant inverse correlation of HbA1C and insulin with superoxide dismutase and catalase in diabetic patients and even stronger inverse correlation in diabetic patients with different complications. This was consistent with the Hunt et al’s proposition that chronic hyperglycemia and hyperinsulinemia may increase oxidative stress [23].

This study also focused on the correlation of MDA with antioxidant enzymes, superoxide dismutase and catalase. The study showed significant inverse correlations of MDA with antioxidant enzymes, superoxide dismutase (SOD) and catalase in diabetic patients, and even stronger inverse correlations were found in diabetic patients with different complications. This evidently showed that oxidative stress in terms of MDA was present in diabetic patients and was still significantly increased in diabetic patients with different complications; this is consistent with the findings of other studies [24, 25, and 26]. Increase in lipid peroxidation products (as indicated by the level of MDA) due to the decrease of the antioxidant enzymes is in line with previous reports [27, 28]. Hence complications of diabetes may be the result of this high level of free radicals (increase in the level of MDA and peroxidation index) and the reduction in antioxidant defences.

The findings of the present study clearly demonstrated that oxidative stress occurred early in diabetes and increased in the course of the disease, leading to diabetic complications. This finding was in line with those of other authors [29].

The present study also focused on the correlation of HbA1c with the MDA. The present study showed significant direct correlation of HbA1c with the MDA in diabetic patients and even stronger significant direct correlation in diabetic patients with different complications.

The direct correlation between glycemic control parameter (HbA1c) and MDA in diabetic patients has been reported by other authors [30, 31], and it can be partially explained by the existing correlation between hyperglycemia, and increased lipid peroxidation.

The present study showed significant direct correlation of HbA1C and MDA with the duration of diabetes in diabetic patients and even stronger significant direct correlation in diabetic patients with different complications. This is in accordance with the study of Kesavulu MM [32] and Sundaram RK [33].

The present study have assessed the effect of malonaldehyde (MDA), antioxidant enzymes; superoxide dismutase and catalase and other factors; glycated hemoglobin (HbA1c), insulin and duration of diabetes independently for the development of diabetic complications i.e., neuropathy, nephropathy, and cardiovascular diseases using the multivariate model. In this multivariate model diabetes mellitus was taken as a control variable for comparison. The
outcome of this multivariate was that, all the oxidative stress biomarkers were found to be independently significantly associated with diabetic complications. Therefore, the overall effect of the individual biomarkers may aggravate the situation and speed up the development of complications. The present study findings have shown that poor glycemic control and long duration of diabetes were associated with nephropathy, neuropathy and cardiovascular disease. This is similar to that reported in several other studies [34, 35].

Conclusions:-
1. The present study confirms susceptibility of diabetic patients to oxidative stress and that poor glycaemic control is associated with free radical-mediated lipid peroxidation.
2. Significantly decreased levels of SOD and catalase, increased levels of MDA in diabetic patients with different complications suggest that oxidative stress plays an important role in the pathogenesis of diabetic complications
3. The present study findings have shown that glycemic control, insulin, MDA, antioxidant enzymes; superoxide dismutase and catalase and duration of diabetes were associated with diabetic complications.

Acknowledgements:--
The authors are grateful to the staff and all the diabetic patients of Jaber Abu Eliz Diabetic Health Center and People Teaching Hospital of the Heart and Chest in Khartoum State. Also grateful acknowledge Laboratory staff of National Research Center in Cairo, to perform the analysis of some parameters of the study.

References:--
1. Hammes HP, Bartmann A, Engel L, Wülfroth P. Antioxidant treatment of experimental diabetic retinopathy in rats with nicanarine. Diabetologia 40: pp.629-634, 1997.
2. Cimato AN, Facorro GB, Piehl LL, Sarrasague MMM, Grinspon D, et al. Oxidative damage and antioxidant status in diabetes mellitus and rheumatoid arthritis: A comparative study. Open Clin Chem J 1:pp.92-98, 2008.
3. MacNee W. Oxidants/antioxidants and COPD. Journal 117 (5_suppl_1): 303S-317S, 2000.
4. S.Davari, S.A.Talaei, H.Alaei, and M.Salami, “Probiotics treatment improves diabetes- induced Impairment of synaptic activity and cognitive function: behavioral and electrophysiological proofs for Microbiome-gut-brain axis,” Neuroscience, vol. 240, pp. 287–296, 2013.
5. P. Chelikani, I. Fita, and P. C. Loewen. Diversity of structures and properties among catalases. Cellular and Molecular Life Sciences, vol. 61, no. 2, pp. 192–208, 2004.
6. K.Takemoto,M.Tanaka,H.Iwataetal. Low catalase activity in blood is associated with the diabetes caused by alloxan. Clinica Chimica Acta, vol. 407, no.1-2, pp. 43–46, 2009.
7. M. Tiedge, S. Lortz, R. Monday, and S. Lenzen. Complementary action of antioxidant enzymes in the protection of bioengineered insulin- producing RINm5F cells against the toxicity of reactive oxygen species. Diabetes, vol. 47, no. 10, pp. 1578–1585, 1998.
8. S. A. Shodehinde and G. Oboh, “Antioxidant properties of aqueous extracts of unripe Musa paradisiaca on sodium nitroprusside induced lipid peroxidation in rat pancreas in Vitro,” Asian Pacific Journal of Tropical Biomedicine, vol. 3, no. 6, pp. 449–457, 2013.
9. Bayens JW, Role of oxidative stress in development of complications in diabetes, Diabetes; 40:pp.405–412, 1991.
10. B. Ramesh, R. Karuna, R. S. Sreenivasa et al., “Effect of Commiphora mukul gum resin on hepatic marker enzymes, lipid peroxidation and antioxidant status in pancreas and heart of streptozotocin induced diabetic rats,” Asian Pacific Journal of Tropical Biomedicine, vol. 2, no. 11, pp. 895–900, 2012.
11. Sharma, B. K. Instrumental Methods of chemical Analysis. 20th ed. Book Code No: CH3-20 / INDIA. Prakashan Media Ltd. P: 45-4, 2001.
12. Goldstein DE,Little RR,Malone J, Nathan D, Peterson CM. Tests of glycemia in diabetes. Diabetes care; 18:pp.896-909, 1995.
13. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95, pp.351–358, 1979.
14. Aebi H. Catalase in vitro. Methods Enzymol. 105, pp.121–126, 1984.
15. Son, S.M. Reactive oxygen and nitrogen species in pathogenesis of vascular complications of diabetes. Diabetes Metab J; 36, pp.190-8, 2012.
16. Dawud FA, Eze ED, Ardja AA, et al. Ameliorative effects of vitamin C and zinc in alloxan-induced diabetes and oxidative stress in Wistar rats. Curr Res J Biol Sci 4:pp.123e9, 2012.
17. N. A. El Boghdady and G. A. Badr, “Evaluation of oxidative stress markers and vascular risk factors in patients with diabetic peripheral neuropathy,” Cell Biochemistry and Function, vol. 30, no. 4, pp. 328–334, 2012.
18. Kimura, F., Hasegawa, G., Obayashi, H., Adachi, T., Haru, H., Ohta, M., Fukui, M., Kitagawa, Y., Park, H., Nakamura, N., Nakano, K., Yoshikawa, T. Serum Extracellular Superoxide Dismutase in Patients with Type 2 Diabetes: Relationship to the development of micro- and macrovascular complications. Diabetes Care., 26, pp.1246-1250, 2003.
19. Uzel N., Sivas A., Uysal M., Oz H. Erythrocyte lipid peroxidation and glutathione peroxidase activities in patients with diabetes mellitus. Horm. Metab. Respp. 19, pp.89—90, 1987.
20. Kedziora-Kornatowska K. Z., Luciak M., Blaszczyk J., Pawlak W. Lipid peroxidation and activities of antioxidant enzymes in erythrocytes of patients with non-insulin dependent diabetes with or without diabetic nephropathy. Nephrol. Dial. Transplant. 13, pp.2829—2832, 1998.
21. Aydin A., Orhan H., Sayal A., Ozata M., Sahin G., Isimer A. Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control. Clin. Biochem. 34, pp. 65—70, 2001.
22. Halliwell, B.; Gutteridge, J.M.C. Free Radicals in Biology and Medicine, 4th ed.; Biosciences Oxford, Oxford University Press Inc.: New York, NY, USA, pp. 127–130, 2007.
23. Hunt J. V., Smith C. C., Wolff S. P. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 39, pp.1420—1424, 1990.
24. Soliman GZA. Blood lipid peroxidation (superoxide dismutase, malondialdehyde, glutathione) levels in Egyptian type 2 diabetes patients. Singapore J 49:pp.129e36, 2008.
25. Ziegler D, Sohr CG, Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care; 27(9):21pp.78-83, 2004.
26. Brownlee, M. The pathological implications of protein glycation. Clin Invest Med 18, pp.275-81, 1995.
27. Okoduwa SIR, Umar A, Ibrahim S, Bel F. Relationship of oxidative stress with type 2 diabetes and hypertension. J Diabetol. 1:1–10, 2013.
28. Kumawat M, Pahwa MB, Gahlaut VS, Singh N. Status of antioxidant enzymes and lipid peroxidation in type2 diabetes mellitus with microvascular complications. Open End J.3:13-6, 2009
29. Lapolla A, Piarulli F, Sartore G, et al. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripher- al artery disease. Diabetes Care. 30: pp.670-676, 2007.
30. Freitas JP, Filipe PM, Rodrigo FG. Lipid peroxidation in type 2 normolipidemic diabetic patients. Diabetes Res Clin Pract. vol.36,no.2 ,pp.71-5, May 1997. https://doi.org/10.1016/S0168-8227 (97)00032-6
31. Slatter DA, Bolton CH, Bailey AJ. The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia.vol.43, no.5, pp.550-7, May2000 https://doi.org/10.1007/s001250051342
32. Kesavulu, M.M., Rao, B.K. and Giri, R. Lipid peroxidation and antioxidant enzyme status in type 2 diabetes with coronary artery disease. Diabetes Res. Clin. Pract. vol.53, no.1, pp.33-9, 2001.
33. Sundaram, R.K., Bhaskar, A. and Vijayalingam, S. Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications. Clin. Science vol.90, no. 4:pp.255-260, 1996.
34. Ayodele OE, Alebiosu CO, Salako BL: Diabetic nephropathy--a review of the natural history, burden, risk factors and treatment. J Natl Med Assoc 96:pp.1445 – 1454, 2004.
35. Schmitz A, Vaeth M: Microalbuminuria: a major risk factor in non-insulindependent diabetes: a 1--year follow-up study of 503 patients. Diabet Med 5:pp.126 – 34, 1987.